Mental Health

BYSANTI™ (milsaperidone): A New FDA-Approved Treatment Offering Hope for Schizophrenia and Bipolar I Disorder

BYSANTI™ (milsaperidone): A New FDA-Approved Treatment Offering Hope for Schizophrenia and Bipolar I Disorder

What is it prescribed for? Bysant ™ is a newly approved medication for treating schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. These serious mental health conditions can deeply affect a person’s thoughts, emotions, and ability to function. Schizophrenia can cause hallucinations, delusions,...

Could GLP-1s Improve Depression?

Could GLP-1s Improve Depression?

Do GLP-1 Drugs Actually Worsen Depression? This Study Looked at Nearly 100,000 People to Find Out GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. But in recent years, concerns have been raised about whether these medications might worsen depression, anxiety, or even increase the risk of self-harm. A large national study published in The Lancet Psychiatry examined this question closely — and the findings may be reassuring for both patients and clinicians. Researchers in Sweden studied nearly 100,000 people with diabetes who already had depression or anxiety. They found that some GLP-1 medications, especially semaglutide, were actually linked to a lower risk of worsening mental illness — not a higher one.

Do GLP-1 Drugs Worsen Depression? A Major Swedish Study Suggests the Opposite

Do GLP-1 Drugs Worsen Depression? A Major Swedish Study Suggests the Opposite

GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. But in recent years, questions have been raised about whether these medications might worsen depression, anxiety, or even increase the risk of self-harm. A large national study published in The Lancet Psychiatry examined this issue closely—and the findings may be reassuring for patients...

Postpartum Depression Breakthrough: Inside the Zuranolone Study

Postpartum Depression Breakthrough: Inside the Zuranolone Study

Postpartum depression (PPD) affects millions of new parents—but a new oral medication may offer faster relief. This breakthrough therapy showed faster results than traditional antidepressants, with many participants seeing improvements within just 15 days. While it’s not a cure-all, zuranolone could represent a major shift in how we support mental health after childbirth.
Talk to your healthcare provider about the full range of options, including therapy, support networks, and this promising new treatment.
Subscribe to ScienceMyHealth for clear, research-based health information.

Does the Shingles Vaccine Lower the Risk of  Dementia?

Does the Shingles Vaccine Lower the Risk of Dementia?

What Did the Research Discover? Researchers wanted to see if the newer recombinant shingles vaccine could lower the risk of dementia. They used a "natural experiment," which means they studied a situation that happened naturally rather than setting up a traditional clinical trial. When the U.S. switched from the older live shingles vaccine to the newer recombinant...

New Medications for Postpartum Depression: Safer Options for Older Mothers

New Medications for Postpartum Depression: Safer Options for Older Mothers

What Did the Research Discover? Postpartum depression (PPD) is a serious mood disorder that affects many new parents after childbirth. It can cause extreme sadness, hopelessness, and difficulty caring for the baby. Current treatments, such as antidepressants, can take weeks to work and may have side effects. In August 2023, the FDA approved zuranolone, the first...